Attenuation by oral N-acetylcysteine of bleomycin-induced lung injury in rats
- PMID: 11491169
- DOI: 10.1183/09031936.01.00049701
Attenuation by oral N-acetylcysteine of bleomycin-induced lung injury in rats
Abstract
Antioxidant therapy may be useful in diseases with impaired oxidant-antioxidant balance such as pulmonary fibrosis. This study examines the effect of N-acetylcysteine (NAC) on bleomycin-induced lung fibrosis in rats. NAC (3 mmol x kg(-1); oral) was given daily from 1 week prior to a single intratracheal instillation of bleomycin (2.5 U x kg(-1)) or saline, until 14 days postinstillation. NAC partially decreased the augmented collagen deposition in bleomycin-exposed rats (hydroxyproline content was 4,354+/-386 and 3,416+/-326 microg x lung(-1) in vehicle-treated and NAC-treated rats, respectively; p < 0.05). The histological assessment using a semiquantitative score showed less collagen deposition and inflammatory cells in NAC-treated rats compared to those receiving bleomycin alone. NAC failed to inhibit the bleomycin-induced increases in lung wet weight and in cell counts and protein levels of bronchoalveolar lavage fluid, but significantly increased total glutathione and taurine levels in bronchoalveolar lavage fluid. These results indicate that oral N-acetylcysteine improves the pulmonary antioxidant protection and may be useful in reducing lung damage produced by bleomycin.
Similar articles
-
Oral N-acetylcysteine reduces bleomycin-induced lung damage and mucin Muc5ac expression in rats.Eur Respir J. 2003 Dec;22(6):900-5. doi: 10.1183/09031936.03.00018003. Eur Respir J. 2003. PMID: 14680076
-
In vivo antioxidant treatment protects against bleomycin-induced lung damage in rats.Br J Pharmacol. 2003 Mar;138(6):1037-48. doi: 10.1038/sj.bjp.0705138. Br J Pharmacol. 2003. PMID: 12684259 Free PMC article.
-
Attenuation of bleomycin-induced lung fibrosis by oral sulfhydryl containing antioxidants in rats: erdosteine and N-acetylcysteine.Pulm Pharmacol Ther. 2005;18(5):367-73. doi: 10.1016/j.pupt.2005.02.001. Epub 2005 Mar 23. Pulm Pharmacol Ther. 2005. PMID: 15939316
-
Mechanisms of bleomycin-induced lung damage.Arch Toxicol. 1991;65(2):81-94. doi: 10.1007/BF02034932. Arch Toxicol. 1991. PMID: 1711838 Review.
-
N-acetylcysteine (NAC) in neurological disorders: mechanisms of action and therapeutic opportunities.Brain Behav. 2014 Mar;4(2):108-22. doi: 10.1002/brb3.208. Epub 2014 Jan 13. Brain Behav. 2014. PMID: 24683506 Free PMC article. Review.
Cited by
-
The bleomycin animal model: a useful tool to investigate treatment options for idiopathic pulmonary fibrosis?Int J Biochem Cell Biol. 2008;40(3):362-82. doi: 10.1016/j.biocel.2007.08.011. Epub 2007 Aug 30. Int J Biochem Cell Biol. 2008. PMID: 17936056 Free PMC article. Review.
-
Genome-wide transcriptional response during the development of bleomycin-induced pulmonary fibrosis in sprague-dawley rats.Toxicol Res. 2010 Jun;26(2):137-47. doi: 10.5487/TR.2010.26.2.137. Toxicol Res. 2010. PMID: 24278517 Free PMC article.
-
Metabolic requirements of pulmonary fibrosis: role of fibroblast metabolism.FEBS J. 2021 Nov;288(22):6331-6352. doi: 10.1111/febs.15693. Epub 2021 Jan 15. FEBS J. 2021. PMID: 33393204 Free PMC article. Review.
-
Lipidomics revealed idiopathic pulmonary fibrosis-induced hepatic lipid disorders corrected with treatment of baicalin in a murine model.AAPS J. 2015 May;17(3):711-22. doi: 10.1208/s12248-014-9714-4. Epub 2015 Mar 12. AAPS J. 2015. PMID: 25762447 Free PMC article.
-
A nutraceutical strategy for downregulating TGFβ signalling: prospects for prevention of fibrotic disorders, including post-COVID-19 pulmonary fibrosis.Open Heart. 2021 Apr;8(1):e001663. doi: 10.1136/openhrt-2021-001663. Open Heart. 2021. PMID: 33879509 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
